Differential changes in GPR55 during microglial cell activation

被引:96
|
作者
Pietr, Maciej [1 ]
Kozela, Ewa [1 ]
Levy, Rivka [1 ]
Rimmerman, Neta [1 ]
Lin, Yi Hsing [2 ,3 ]
Stella, Nephi [2 ,3 ]
Vogel, Zvi [1 ,4 ]
Juknat, Ana [4 ]
机构
[1] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel
[2] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[4] Tel Aviv Univ, Sackler Fac Med, Dr Miriam & Sheldon G Adelson Ctr Biol Addict Dis, Tel Aviv, Israel
关键词
Cannabinoid; Microglia; Lipopolysaccharide; Interferon gamma; G protein-coupled receptor 55; CB2; receptor; Lysophosphatidylinositol; ERK phosphorylation; CB2 CANNABINOID RECEPTOR; EXPRESSION; BRAIN; ANANDAMIDE; GAMMA;
D O I
10.1016/j.febslet.2009.05.028
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We examined how lipopolysaccharide (LPS) and interferon gamma (IFN-gamma), known to differentially activate microglia, affect the expression of G protein-coupled receptor 55 (GPR55), a novel cannabinoid receptor. We found that GPR55 mRNA is significantly expressed in both primary mouse microglia and the BV-2 mouse microglial cell line, and that LPS down-regulates this message. Conversely, IFN-gamma slightly decreases GPR55 mRNA in primary microglia, while it upregulates this message in BV-2 cells. Moreover, the GPR55 agonist, lysophosphatidylinositol, increases ERK phosphorylation in BV-2 stimulated with IFN-gamma, in correlation with the increased amount of GPR55 mRNA. Remarkably, these stimuli-induced changes in GPR55 expression are similar to those observed with CB2-R, suggesting that both receptors might be involved in neuroinflammation and that their expression is concomitantly controlled by the state of microglial activation. (C) 2009 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
引用
收藏
页码:2071 / 2076
页数:6
相关论文
共 50 条
  • [1] Activation of GPR55 alleviates neuropathic pain and chronic inflammation
    Jiang, Weiqun
    Yu, Wenbin
    Tan, Yu
    BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2025, 72 (01) : 196 - 206
  • [2] GPR55: a new promising target for metabolism?
    Tuduri, Eva
    Imbernon, Monica
    Javier Hernandez-Bautista, Rene
    Tojo, Marta
    Ferno, Johan
    Dieguez, Carlos
    Nogueiras, Ruben
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2017, 58 (03) : R191 - R202
  • [3] Anti-neuroinflammatory effects of GPR55 antagonists in LPS-activated primary microglial cells
    Saliba, Soraya Wilke
    Jauch, Hannah
    Gargouri, Brahim
    Keil, Albrecht
    Hurrle, Thomas
    Volz, Nicole
    Mohr, Florian
    van der Stelt, Mario
    Braese, Stefan
    Fiebich, Bernd L.
    JOURNAL OF NEUROINFLAMMATION, 2018, 15
  • [4] The enigmatic pharmacology of GPR55
    Ross, Ruth A.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2009, 30 (03) : 156 - 163
  • [5] Pharmacological Activation of GPR55 Improved Cognitive Impairment Induced by Lipopolysaccharide in Mice
    Wang, Xin
    Xiang, Xiaotong
    Hu, Jie
    Wu, Yumei
    Li, Yueyue
    Jin, Shiyu
    Wu, Xian
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2022, 72 (08) : 1656 - 1669
  • [6] A potential role for GPR55 in gastrointestinal functions
    Schicho, Rudolf
    Storr, Martin
    CURRENT OPINION IN PHARMACOLOGY, 2012, 12 (06) : 653 - 658
  • [7] GPR55, a Lysophosphatidylinositol Receptor with Cannabinoid Sensitivity?
    Nevalainen, Tapio
    Irving, Andrew J.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2010, 10 (08) : 799 - 813
  • [8] GPR55: From orphan to metabolic regulator?
    Liu, Bo
    Song, Shuang
    Jones, Peter M.
    Persaud, Shanta J.
    PHARMACOLOGY & THERAPEUTICS, 2015, 145 : 35 - 42
  • [9] The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling
    Calvillo-Robledo, Argelia
    Daniel Cervantes-Villagrana, Rodolfo
    Morales, Paula
    Marichal-Cancino, Bruno A.
    LIFE SCIENCES, 2022, 301
  • [10] GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors
    Zhao, Pingwei
    Abood, Mary E.
    LIFE SCIENCES, 2013, 92 (8-9) : 453 - 457